RVAC Completes Its Series B financing
RVAC Medicines Pte. Ltd. (“RVAC”), an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group (“CBC”), recently announced the completion of its series B financing, bringing the company’s total funds raised since its inception in June 2021 to US$140 million. RVAC aims to address unmet medical needs, particularly in emerging markets, through novel vaccines and therapeutics including […]
